SPOTLIGHT: FDA greenlights Pozen Phase III
The FDA has given Pozen a green light for its Phase III trial of PN 2000 for arthritis. The Chapel Hill, NC-based drug developer says it should begin the pivotal trial in the next few months. Pozen was dealt a significant blow last summer when the FDA rejected its MT 100 for migraines. Report
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
